Navarrabiomed
Pamplona, Navarre, 31012, Spain
NCT Number: NCT07371325
The aim of the present study is to evaluate the effectiveness of the addition of the postbiotic Pediococcus acidilactici (pA1c®HI) on amelioration of metabolic disturbances in patients with (FEP) or (SSD) treated with antipsychotic drugs.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Pamplona, Navarre, 31012, Spain
This study aims to evaluate the effectiveness of an add-on postbiotic (Pediococcus acidilactici, pA1c®HI) to antipsychotic drugs on metabolic disturbances and psychopathological dimensions in patients diagnosed with first episode psychotic (FEP) or schizophrenia spectrum disorder (SSD).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This study is the first study based on postbiotics instead of probiotics, pA1C®HI will be included as add on to the treatment with atypical antipsychotics in patients diagnosed with FEP or SSD. We include in our study the monitoring of glucose levels by means of sensors that will allow not only the recording of these average daily and weekly glucose levels but also the physical activity performed by the participant along the whole study. We also analyze the microbiota, responsible for metabolic functions, through metatranscriptome of intestinal microbiota from faecal samples from participants
This study participants will continue with their established drug treatment as prescribed by their referring therapists. In the event of any changes to the treatment, the appropriate record will be made.
Time frame: Beginning (week 0) and end of the study (week 12).
Description: Measurement of total cholesterol in the blood. Includes LDL, HDL, and other fractions. It is a general marker of cardiovascular risk.
Units: mg/dL
Ranges:
Desirable: < 200 mg/dL
High limit: 200-239 mg/dL
High: ≥ 240 mg/dL
Time frame: Beginning (week 0) and end of the study (week 12)
Description: Known as "bad cholesterol." High levels are associated with atherosclerosis and cardiovascular disease.
Units: mg/dL
Ranges:
Optimal: < 100 mg/dL
Near optimal: 100-129 mg/dL
High limit: 130-159 mg/dL
High: 160-189 mg/dL
Very high: ≥ 190 mg/dL
Time frame: Beginning (week 0) and end of the study (week 12)
Description: Known as "good cholesterol." Helps remove cholesterol from the arteries.
Units: mg/dL
Ranges:
Low (cardiovascular risk):
Men: < 40 mg/dL
Women: < 50 mg/dL
Adequate/protective: ≥ 60 mg/dL
Time frame: Beginning (week 0) and end of the study (week 12)
Description: Type of fat in the blood related to energy metabolism. High values are associated with metabolic syndrome and cardiovascular risk.
Units: mg/dL
Ranges (fasting):
Normal: < 150 mg/dL
High limit: 150-199 mg/dL
High: 200-499 mg/dL
Very high: ≥ 500 mg/dL
Time frame: Beginning (week 0) and end of the study (week 12)
Description: Blood glucose concentration, a key indicator of carbohydrate metabolism.
Units: mg/dL
Ranges (fasting):
Normal: 70-99 mg/dL
Impaired fasting glucose (prediabetes): 100-125 mg/dL
Diabetes: ≥ 126 mg/dL
Time frame: Beginning (week 0) and end of the study (week 12)
Description: Hormone produced by the pancreas that regulates glucose uptake by tissues.
Units: µU/mL (or mIU/L)
Ranges (fasting):
Approximate normal: 2-25 µU/mL
Elevated values may suggest insulin resistance.
Time frame: Beginning (week 0) and end of the study (week 12)
Description: Reflects the average blood glucose level over the past 2-3 months.
Units: %
Ranges:
Normal: < 5.7%
Prediabetes: 5.7-6.4%
Diabetes: ≥ 6.5%
Time frame: Beginning (week 0) and end of the study (week 12)
Description: Index that estimates insulin resistance, calculated from fasting glucose and insulin.
Formula:
HOMA-IR = Insulin (µU/mL) × Glucose (mg/dL) / 405
Units: No units (index)
Guideline ranges:
Normal: < 2.0
Mild insulin resistance: 2.0-2.9
Significant insulin resistance: ≥ 3.0
Time frame: Along the study: week 0, week 6, and week 12
Positive and Negative Symptoms
Description: A widely used clinical scale for assessing the severity of positive and negative symptoms and general psychopathology in schizophrenia and other psychotic disorders.
Structure: 30 items divided into:
Positive subscale (7 items)
Negative subscale (7 items)
General psychopathology (16 items)
Scoring: Each item is scored from 1 (absent) to 7 (extreme).
Ranges:
Total score: 30-210
The higher the score, the greater the symptom severity.
Guideline interpretation (total):
Mild: ~58-75
Moderate: ~75-95
Severe: >95
Time frame: Along the study: week 0, week 6, and week 12
Description: Instrument designed specifically to assess negative symptoms in detail.
Domains assessed (6):
Anhedonia
Asociality
Avolition
Affective flattening
Alogia
Lack of emotional distress
Structure: 13 items
Scoring: Items scored from 0 (absent) to 6 (severe).
Total range: 0-78
Interpretation:
Higher scores indicate greater severity of negative symptoms.
Time frame: Along the study: week 0, week 6, and week 12
Cognitive symptoms 3. Screening for Cognitive Impairment in Psychiatry (SCIP)
Description: Brief test for detecting cognitive impairment in psychiatric patients.
Domains assessed:
Verbal learning
Working memory
Verbal fluency
Processing speed
Delayed memory
Duration: ~15 minutes
Scoring: Approximate total scale 0-100 (depending on version).
Interpretation:
Lower scores indicate greater cognitive impairment.
Cut-off points adjusted for age and educational level are used.
Time frame: Along the study: week 0, week 6, and week 12
Description: Standardized reference battery for assessing cognition in schizophrenia.
Domains assessed (7):
Processing speed
Attention/vigilance
Working memory
Verbal learning
Visual learning
Reasoning and problem solving
Social cognition
Score:
T scores (mean = 50, SD = 10)
Interpretation:
T < 40: below-average performance
T 40-60: normal range
T > 60: above-average performance
Time frame: Along the study: week 0, week 6, and week 12
Description: Scale designed to estimate cognitive reserve, considering premorbid and sociocultural factors.
Areas assessed:
Educational level
Occupation
Cognitive and leisure activities
Premorbid intellectual level
Score: Composite index (no units).
Interpretation:
Higher scores indicate greater cognitive reserve, associated with a better functional prognosis.
Affective symptoms 6. Calgary Depression Scale for Schizophrenia (CDSS)
Description: Specific scale for assessing depressive symptoms in patients with schizophrenia, differentiating them from negative or extrapyramidal symptoms.
Structure: 9 items
Scoring: Items from 0 (absent) to 3 (severe).
Total range: 0-27
Interpretation:
≥ 6 points suggests the presence of clinically significant depression.
Time frame: Along the study: week 0, week 6, and week 12
Motor symptoms 7. Simpson-Angus Scale (SAS)
Description: Instrument for assessing extrapyramidal symptoms, especially antipsychotic-induced parkinsonism.
Structure: 10 items
Scoring: Items from 0 (normal) to 4 (severe).
Total score: Average of items or total sum.
Interpretation:
Higher scores indicate greater severity of motor symptoms.
Time frame: Along the study: week 0, week 6, and week 12
Overall functioning 8. Global Assessment of Functioning Scale (GAF)
Description: Global scale that assesses psychological, social, and occupational functioning.
Range: 0-100
Interpretation:
91-100: superior functioning
71-90: minimal symptoms
51-70: mild symptoms
31-50: severe symptoms
≤ 30: severe impairment of functioning
Time frame: Along the study: week 0, week 6, and week 12.
Description: Measurement of the individual's total body mass.
Units: kilograms (kg)
Reference ranges:
There are no universal "normal" ranges, as weight must be interpreted in relation to height, sex, and body composition. It is mainly used to calculate BMI.
Time frame: Along the study: week 0, week 6, and week 12
Description: Body length measured in an upright position, from the soles of the feet to the top of the head.
Units: centimeters (cm) or meters (m)
Reference ranges:
Variable depending on sex, age, and ethnicity; used primarily to calculate BMI.
Time frame: Along the study: week 0, week 6, and week 12
Description: Indirect indicator of body fat that relates weight to height.
Formula:
BMI = weight (kg)/height (m)2
Units: kg/m²
Ranges (WHO):
Underweight: < 18.5 kg/m²
Normal weight: 18.5-24.9 kg/m²
Overweight: 25.0-29.9 kg/m²
Grade I obesity: 30.0-34.9 kg/m²
Obesity grade II: 35.0-39.9 kg/m²
Obesity grade III: ≥ 40 kg/m²
Time frame: Along the study: week 0, week 6, and week 12
Description: Measurement of abdominal circumference, used as an indicator of visceral fat and cardiometabolic risk.
Units: centimeters (cm)
Cut-off points (cardiometabolic risk):
Men: ≥ 102 cm
Women: ≥ 88 cm (Some European criteria use ≥94 cm in men)
Time frame: Along the study: week 0, week 6, and week 12
Description: Number of heartbeats per minute at rest.
Units: beats per minute (bpm)
Ranges (resting, adults):
Normal: 60-100 bpm
Bradycardia: < 60 bpm
Tachycardia: > 100 bpm
Time frame: Along the study: week 0, week 6, and week 12
Description: Force exerted by blood against arterial walls, expressed as systolic/diastolic pressure.
Units: millimeters of mercury (mmHg)
Ranges (clinical guidelines):
Normal: < 120 / < 80 mmHg
Elevated: 120-129 / < 80 mmHg
Grade 1 hypertension: 130-139 / 80-89 mmHg
Grade 2 hypertension: ≥ 140 / ≥ 90 mmHg
Time frame: Along the study: week 0, week 6, and week 12
Description: Measurement of subcutaneous adipose tissue thickness using a skinfold caliper; allows estimation of body fat percentage.
Units: millimeters (mm)
Common measurement sites:
Triceps
Subscapular
Suprailiac
Abdominal
Thigh
Reference ranges:
There are no universal values; results are interpreted:
By summing skinfolds
By applying predictive equations (e.g., Durnin-Womersley, Jackson-Pollock)
Interpretation:
Higher values indicate greater subcutaneous adiposity.
Manuel Jesús Cuesta Zurita
Other
Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.
Acronym: GLUCOPSICO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07190352
Mental Disorders, Nicotine Use
Boston, Massachusetts, United States
View Trial DetailsNCT07550387
Mental Disorders, SCHIZOPHRENIA 1 (Disorder)
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07512843
Hospitalized Adult Patients, Mental Disorders
Zarqa, Jordan
View Trial DetailsNCT07452835
Anxiety Disorders, Depressive Disorder
Cairo, Menofia, Egypt
View Trial Details